OSE2101 Clinical Trials (2026): 5 Studies for Locally Advanced Cancer & Lymphoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 OSE2101 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Locally Advanced Cancer & Lymphoma) and 909 total planned enrollment. 2 Phase 3 OSE2101 trials and 2 Phase 2 are listed. 2 OSE2101 clinical trials are actively recruiting at 31 U.S. sites across 14 states. Most recent activity: NCT05751798 (Dec 2029).
Where to Participate: All OSE2101 Trial Sites in the U.S. (31 sites across 14 states)
Every actively recruiting OSE2101trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Clinical Research Advisors, LLC | Beverly Hills90211 | NCT06472245 | Map |
| CO | Lutheran Medical Center - Cancer Centers of Colorado | Wheat Ridge80033-6013 | NCT06472245 | Map |
| CT | Eastern Connecticut Hematology and Oncology Associates | Norwich06360 | NCT06472245 | Map |
| DC | Georgetown Lombardi Comprehensive Cancer Center | Washington D.C.20007 | NCT06472245 | Map |
| FL | Cancer Specialists of North Florida - Fleming Island | Fleming Island32003 | NCT06472245 | Map |
| FL | Cancer Specialists of North Florida - Southpoint | Jacksonville32256-6932 | NCT06472245 | Map |
| FL | Cancer Specialists of North Florida | Jacksonville Beach32250 | NCT06472245 | Map |
| FL | Cancer Specialists Of North Florida - St. Augustine | Saint Augustine32086 | NCT06472245 | Map |
| FL | Comprehensive Hematology Oncology | St. Petersburg33709 | NCT06472245 | Map |
| FL | Comprehensive Hematology Oncology - Trinity Clinic | Trinity34655 | NCT06472245 | Map |
| IL | University of Illinois Cancer Center | Chicago60612 | NCT06472245 | Map |
| LA | Pontchartrain Cancer Center - Covington Office | Covington70433 | NCT06472245 | Map |
| LA | Pontchartrain Cancer Center - Hammond Office | Hammond70403-1452 | NCT06472245 | Map |
| MD | Ascension Saint Agnes Hospital | Baltimore21229 | NCT06472245 | Map |
| MA | University of Massachusetts Memorial Medical Center | Worcester01655 | NCT06472245 | Map |
| NE | Nebraska Hematology-Oncology - Revive Research Institute LLC | Lincoln68506 | NCT06472245 | Map |
| NY | New York Cancer & Blood Specialists - Cancer Center - Research Headquarters | New York10028 | NCT06472245 | Map |
| NY | New York Cancer & Blood Specialists - Patchogue Medical Oncology | Patchogue11772 | NCT06472245 | Map |
| SC | Bon Secours Hematology and Oncology | Greenville29607 | NCT06472245 | Map |
| TN | Tennessee Oncology - Chattanooga - Downtown | Chattanooga37403 | NCT06472245 | Map |
| TN | Tennessee Oncology - Chattanooga - GHCR Site I | Chattanooga37403 | NCT06472245 | Map |
| TN | Tennessee Oncology - Chattanooga - Memorial Plaza | Chattanooga37404 | NCT06472245 | Map |
| TN | Tennessee Oncology - Cleveland Clinic | Cleveland37311 | NCT06472245 | Map |
| TN | Tennessee Oncology - Franklin Clinic | Franklin37067 | NCT06472245 | Map |
| TN | Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR) - Corporate | Nashville37232 | NCT06472245 | Map |
| TN | Tennessee Oncology - Nashville - St. Thomas West Clinic | Nashville37205 | NCT06472245 | Map |
| TN | Tennessee Oncology - Shelbyville Clinic | Shelbyville37160 | NCT06472245 | Map |
| TN | Tennessee Oncology - Smyrna Clinic | Smyrna37167 | NCT06472245 | Map |
| WA | Northwest Medical Specialties - Gig Harbor | Gig Harbor98332 | NCT06472245 | Map |
| WA | Northwest Medical Specialties - Puyallup Medical Oncology | Puyallup98373 | NCT06472245 | Map |
| WA | Northwest Medical Specialties - Tacoma | Tacoma98405 | NCT06472245 | Map |
OSE2101 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | terminated | Total |
|---|---|---|---|---|
| P1/P2 | 1 | 1 | ||
| P2 | 2 | 2 | ||
| P3 | 1 | 1 | 2 |
Recruiting OSE2101 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05751798 | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas | P1/P2 | Solid Advanced Tumor | 41 | Dec 2022 |
| NCT06472245 | ARTEMIATrial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | P3 | Patients With Non-Small Cell Lung Cancer | 363 | Dec 2024 |
OSE2101 clinical trials by indication
Patients With Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06472245 | ARTEMIA | P3 | recruiting | Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor |
Solid Advanced Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05751798 | — | P1/P2 | recruiting | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas |
Platinum-sensitive Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04713514 | TEDOVA | P2 | active not recruiting | OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC |
Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03806309 | TEDOPAM | P2 | active not recruiting | OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC |
Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02654587 | ATALANTE-1 | P3 | terminated | OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure |
OSE2101 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ARTEMIA | NCT06472245 | P3 | recruiting | Patients With Non-Small Cell Lung Cancer | 363 | — |
| ATALANTE-1 | NCT02654587 | P3 | terminated | Non Small Cell Lung Cancer | 219 | PMID 37704166 |
| TEDOVA | NCT04713514 | P2 | active not recruiting | Platinum-sensitive Ovarian Cancer | 180 | PMID 39155847 |
| TEDOPAM | NCT03806309 | P2 | active not recruiting | Pancreatic Ductal Adenocarcinoma | 106 | — |
Terminated and withdrawn OSE2101 trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT02654587terminatedOSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
All OSE2101 trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05751798 | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas | P1/P2 | recruiting | 41 | OSE Immunotherapeutics | Dec 2022 | |
| NCT06472245 | ARTEMIA | Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | P3 | recruiting | 363 | OSE Immunotherapeutics | Dec 2024 |
| NCT04713514 | TEDOVA | OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC | P2 | active not recruiting | 180 | ARCAGY/ GINECO GROUP | Aug 2021 |
| NCT03806309 | TEDOPAM | OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC | P2 | active not recruiting | 106 | GERCOR - Multidisciplinary Oncology Cooperative Group | Apr 2021 |
| NCT02654587 | ATALANTE-1 | OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure | P3 | terminated | 219 | OSE Immunotherapeutics | Feb 2016 |
OSE2101 clinical trials: frequently asked questions
- How many OSE2101 clinical trials are there?
- 5 OSE2101 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are OSE2101 clinical trials recruiting in 2026?
- Yes — 2 OSE2101 trials are actively recruiting in 2026, with 31 U.S. sites across 14 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is OSE2101 being studied for?
- OSE2101 is being studied for Locally Advanced Cancer, Lymphoma, Metastatic Cancer, Non Small Cell Lung Cancer, NSCLC (Non-small Cell Lung Cancer) and 5 more. The trials are grouped by indication on this page.
- What phase is OSE2101 in?
- OSE2101 clinical trials span 2 Phase 3, 2 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors OSE2101 clinical trials?
- The lead sponsor across the most OSE2101 trials is OSE Immunotherapeutics, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming OSE2101as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: